Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

NUVB
Nuvation Bio Inc.
stock NYSE

At Close
Oct 1, 2026 3:59:59 PM EDT
5.55USD-0.893%(-0.05)3,471,515
0.00Bid   0.00Ask   0.00Spread
Pre-market
Oct 1, 2026 9:28:30 AM EDT
5.65USD+0.893%(+0.05)20,993
After-hours
Oct 1, 2026 4:49:30 PM EDT
5.50USD-0.901%(-0.05)651
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:52AM EST  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Jan. 20, 2022: ETSY, NUVB, TRV, EH, NFLX   Benzinga
08:44AM EST  FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors   Benzinga
07:27AM EST  Nuvation Bio Says FDA Clears IND Application For NUV-868   RTTNews
07:09AM EST  Nuvation Bio Announces FDA Clearance Of IND Application For NUV-868 For Advanced Solid Tumors   RTTNews
07:05AM EST  Nuvation Bio Announces FDA Clearance Of Investigational New Drug Application For NUV-868 For The Treatment Of Advanced Solid Tumors   Benzinga
07:01AM EST  Nuvation Bio Announces FDA Clearance of Investigational New Drug Application   PR Newswire
Jan 10, 2022
07:01AM EST  Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones   PR Newswire
Dec 17, 2021
08:00AM EST  Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in   PR Newswire
Dec 15, 2021
07:24AM EST  Nuvation Bio Inc. (NUVB) said the FDA has granted Fast Track designation to NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, for the treatment of patients with high-grade gliomas, including glioblastoma multiforme. NUV-422 is the company's lead investigational CDK2/4/6 inhibitor program.   RTTNews
07:06AM EST  Nuvation Bio Receives FDA Fast Track Designation For NUV-422 For The Treatment Of High-Grade Gliomas,   RTTNews
07:06AM EST  Nuvation Bio Receives FDA Fast Track Designation For NUV-422 For The Treatment Of High-Grade Gliomas, Including Glioblastoma Multiforme   Benzinga
07:01AM EST  Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment   PR Newswire
Dec 13, 2021
07:49AM EST  Nuvation Bio: FDA Clears IND Application For NUV-422 For Prostate Cancer   RTTNews
07:03AM EST  Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer   Benzinga
07:01AM EST  Nuvation Bio Announces FDA Clearance of Investigational New Drug Application   PR Newswire
Dec 8, 2021
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
07:53AM EST  Nuvation Bio Inc. (NUVB) said that the U.S. Food and Drug Administration has cleared its investigational new drug application to evaluate NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of advanced breast cancer.   RTTNews
07:16AM EST  Nuvation Bio : FDA Clears IND Application For NUV-422 For Treatment Of Advanced Breast Cancer   RTTNews
07:03AM EST  Nuvation Bio Announces FDA Clearance Of Investigational New Drug Application For NUV-422 For The Treatment Of Advanced Breast Cancer   Benzinga
07:01AM EST  Nuvation Bio Announces FDA Clearance of Investigational New Drug Application   PR Newswire
Nov 10, 2021
05:27PM EST  Nuvation Reports Q2 2021 Cash, Cash Equivalents $791.8M   Benzinga
04:06PM EST  Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business   PR Newswire
Aug 12, 2021
04:06PM EDT  Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides   PR Newswire
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jun 1, 2021
07:01AM EDT  Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations   PR Newswire
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
07:01AM EDT  Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference   PR Newswire
May 17, 2021
05:03PM EDT  Nuvation Bio Q1 EPS $(0.12) Down From $(0.10) YoY   Benzinga
05:01PM EDT  Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business   PR Newswire
Apr 18, 2021
08:52AM EDT  Last Week's Notable Insider Buys Included Evergy, StoneMor, Tattooed Chef And More   Benzinga
Apr 6, 2021
10:55AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2021   Benzinga
09:26AM EDT  RBC Capital Initiates Coverage On Nuvation Bio with Outperform Rating, Announces Price Target of $15   Benzinga
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
05:17PM EST  Nuvation Bio FY20 Loss $40.523M vs $33.13M In FY19   Benzinga
05:15PM EST  Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business   PR Newswire
07:18AM EST  Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas   Benzinga
07:08AM EST  Nuvation Bio: FDA Grants Orphan Drug Designation For NUV-422 For Patients With Malignant Gliomas   RTTNews
07:01AM EST  Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of   PR Newswire
Mar 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
09:33AM EST  Cowen & Co. Initiates Coverage On Nuvation Bio with Outperform Rating   Benzinga
09:25AM EST  Jefferies Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $20   Benzinga
08:37AM EST  BMO Capital Initiates Coverage On Nuvation Bio with Outperform Rating, Announces Price Target of $16   Benzinga
08:14AM EST  Wedbush Initiates Coverage On Nuvation Bio with Outperform Rating, Announces Price Target of $20   Benzinga
06:55AM EST  BTIG Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $16   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC